Skip to content
    Agent Capital logo

    Agent Capital

    Waltham, Massachusetts, United StatesFounded 2016
    www.agentcapital.comLinkedIn
    HealthcareBiotech & Life Sciences

    Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs. The firm invests across all stages of development, from early-stage seed rounds to later-stage crossover and PIPE financings.

    48% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (41% of deals). Average disclosed round size is $59.1M (across 50 rounds with reported amounts).

    Find people at Agent Capital on Goldilocks AI

    Portfolio

    41

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    2

    Team

    PN

    Preston Noon, PharmD, MBA

    Partner, Co-Founder

    GV

    Geeta Vemuri, PhD, MBA

    Managing Partner, Founder

    BP

    Bruce Peacock

    Operating Partner

    JG

    John Glasspool

    Venture Partner

    JO

    John Orloff, MD

    Venture Partner

    AD

    Anthony DiNatale, PhD

    Vice President

    LK

    Lisa Kraeutler

    VP of Fund Finance

    MM

    Marla McMillan, MBA

    VP of Fund Finance

    KN

    Kirti Nimmala, MS

    Investment Associate

    VA

    Venkata Aditya Kalaga, MTM

    Investment Analyst

    JG

    Julie Gionfriddo

    Head of Investor Relations and Fundraising

    LF

    Lori Forrest, CPA

    Controller

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    58 investments
    CompanyRoundAmountDate
    Flare Therapeutics logoFlare TherapeuticsSeries C—Jun 2026
    The General Intelligence Company logoThe General Intelligence CompanySeed$8.7MDec 2025
    Composio logoComposioSeries A$29MJul 2025
    GlycoEra logoGlycoEraSeries B$130MMay 2025
    Star Therapeutics logoStar TherapeuticsSeries D$125MJan 2025
    Weave logoWeaveSeries A—Jan 2025
    Weave logoWeaveSeries A—Jan 2025
    Hone Health logoHone HealthSeries A$33MJan 2025
    Composio logoComposioSeries A$25MJan 2025
    Cerevance logoCerevanceSeries C$51MApr 2024
    VVittoriaSeed$25MJan 2024
    Foresight Diagnostics logoForesight DiagnosticsSeries B$58.8MApr 2023
    Orbital Therapeutics logoOrbital TherapeuticsSeries A$270MApr 2023
    ViTToria Biotherapeutics logoViTToria BiotherapeuticsSeries A$15MJan 2023
    VVittoriaSeries A$15MJan 2023
    Carbon Biosciences logoCarbon BiosciencesSeries A$38MJun 2022
    IImCheck TherapeuticsSeries C—Jun 2022
    Cyrus Biotechnology logoCyrus BiotechnologyUnknown$18MDec 2021
    Immunitas Therapeutics logoImmunitas TherapeuticsSeries B$58MAug 2021
    IImmunitasSeries B$58MAug 2021
    Interius BioTherapeutics logoInterius BioTherapeuticsSeries A$76MMay 2021
    Entrada Therapeutics logoEntrada TherapeuticsSeries B$116MMar 2021
    CCarisma Therapeutics, Inc.Series B—Mar 2021
    IImmunitasSeries B$58MJan 2021
    Entrada logoEntradaSeries B$116MJan 2021
    Page 1 of 3

    Top Co-Investors

    Alexandria Venture Investments12 shared
    MRL Ventures Fund10 shared
    Wellington Management9 shared
    RA Capital Management7 shared
    Longwood Fund6 shared
    Cormorant Asset Management6 shared
    Osage University Partners6 shared
    Pfizer Ventures6 shared
    Qatar Investment Authority6 shared
    Solasta Ventures6 shared
    Roche Venture Fund6 shared
    MPM Capital6 shared
    TPG Biotech5 shared
    HealthCap5 shared
    BrightEdge5 shared
    Cowen Healthcare Investments5 shared
    Redmile Group5 shared
    Grazia Equity4 shared
    Y Combinator4 shared
    Leaps by Bayer4 shared

    Last updated: 20 October 2026